Free immunoglobulin light chains as a risk factor in renal and extrarenal complications

Seminars in Dialysis

Volumn 22, Issue 4, 2009, Pages 369-372

  Cohen, Gerald ^a   Hörl, Walter H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN;

ARTICLE; HUMAN; KIDNEY DISEASE; METABOLISM; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; RENAL DIALYSIS; RISK FACTORS;

EID: 69249113770     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2009.00582.x     Document Type: Article

References (38)

1. Hannam-Harris AC, Gordon J, Smith JL : Immunoglobulin synthesis by neoplastic B lymphocytes: free light chain synthesis as a marker of B cell differentiation. J Immunol 125 : 2177 2181, 1980
2. Solling K : Free light chains of immunoglobulins. Scand J Clin Lab Invest Suppl 157 : 1 83, 1981
3. Clark WR, Gao D : Low-molecular weight proteins in end-stage renal disease: potential toxicity and dialytic removal mechanisms. J Am Soc Nephrol 13 : S41 S47, 2002
4. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D : Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int 16 : 251 270, 1979
5. Christensen EI, Birn H : Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 280 : F562 F573, 2001
6. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P : Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 3 : 1684 1690, 2008
7. Solling K, Solling J, Romer FK : Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med Scand 209 : 473 477, 1981
8. Moutsopoulos HM, Steinberg AD, Fauci AS, Lane HC, Papadopoulos NM : High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren's syndrome. J Immunol 130 : 2663 2665, 1983
9. Fagnart OC, Sindic CJ, Laterre C : Free kappa and lambda light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. J Neuroimmunol 19 : 119 132, 1988
10. Hopper JE, Golbus J, Meyer C, Ferrer GA : Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J Clin Immunol 20 : 123 137, 2000
11. Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA : Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci 29 : 170 174, 2008
12. Cohen G, Rudnicki M, Schmaldienst S, Hörl WH : Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. Nephrol Dial Transplant 17 : 879 883, 2002
13. Wakasugi K, Sasaki M, Suzuki M, Azuma N, Nobuto T : Increased concentrations of free light chain lambda in sera from chronic hemodialysis patients. Biomater Artif Cells Immobilization Biotechnol 19 : 97 109, 1991
14. Cserti C, Haspel R, Stowell C, Dzik W : Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 47 : 511 514, 2007
15. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR : Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 18 : 886 895, 2007
16. Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, Cockwell P : European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 9 : 55, 2008
17. Pozzi C, Locatelli F : Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol 22 : 319 330, 2002
18. Gallo G, Goni F, Boctor F, Vidal R, Kumar A, Stevens FJ, Frangione B, Ghiso J : Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits. Am J Pathol 148 : 1397 1406, 1996
19. Bhargava P, Rushin JM, Rusnock EJ, Hefter LG, Franks TJ, Sabnis SG, Travis WD : Pulmonary light chain deposition disease: report of five cases and review of the literature. Am J Surg Pathol 31 : 267 276, 2007
20. Kagimoto T, Nakakuma H, Hata H, Hidaka M, Horikawa K, Kawaguti T, Nagakura S, Iwamoto N, Shirono K, Kawano F, Takatsuki K : Differential glycosylation of Bence Jones protein and kidney impairment in patients with plasma cell dyscrasia. J Lab Clin Med 129 : 217 223, 1997
21. Omtvedt LA, Bailey D, Renouf DV, Davies MJ, Paramonov NA, Haavik S, Husby G, Sletten K, Hounsell EF : Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid 7 : 227 244, 2000
22. Deret S, Chomilier J, Huang DB, Preud'homme JL, Stevens FJ, Aucouturier P : Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease. Protein Eng 10 : 1191 1197, 1997
23. Huang ZQ, Sanders PW : Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest 73 : 810 817, 1995
24. Nicastri AL, Prado MJ, Dominguez WV, Prado EB : Nephrotoxicity of Bence-Jones proteins: interference in renal epithelial cell acidification. Braz J Med Biol Res 35 : 357 360, 2002
25. Guan S, el-Dahr S, Dipp S, Batuman V : Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J Investig Med 47 : 496 501, 1999
26. Sikkink LA, Ramirez-Alvarado M : Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases. Amyloid 15 : 29 39, 2008
27. Teng J, Zhang PL, Russell WJ, Zheng LP, Jones ML, Herrera GA : Insights into mechanisms responsible for mesangial alterations associated with fibrogenic glomerulopathic light chains. Nephron Physiol 94 : 28 38, 2003
28. Zhu L, Herrera GA, Murphy-Ullrich JE, Huang ZQ, Sanders PW : Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. Am J Pathol 147 : 375 385, 1995
29. Li M, Balamuthusamy S, Simon EE, Batuman V : Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. Am J Physiol Renal Physiol 295 : F82 F90, 2008
30. Cohen G, Haag-Weber M, Mai B, Deicher R, Hörl WH : Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J Am Soc Nephrol 6 : 1592 1599, 1995
31. Descamps-Latscha B, Herbelin A, Nguyen AT, Zingraff J, Jungers P, Chatenoud L : Immune system dysregulation in uremia. Semin Nephrol 14 : 253 260, 1994
32. Jacobson DR, Zolla-Pazner S : Immunosuppression and infection in multiple myeloma. Semin Oncol 13 : 282 290, 1986
33. Pratt G, Goodyear O, Moss P : Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138 : 563 579, 2007
34. Heinzelmann M, Mercer-Jones MA, Passmore JC : Neutrophils and renal failure. Am J Kidney Dis 34 : 384 399, 1999
35. Cohen G, Rudnicki M, Deicher R, Hörl WH : Immunoglobulin light chains modulate polymorphonuclear leucocyte apoptosis. Eur J Clin Invest 33 : 669 676, 2003
36. Sun M, Li L, Gao QS, Paul S : Antigen recognition by an antibody light chain. J Biol Chem 269 : 734 738, 1994 (Pubitemid 24026721)
37. Redegeld FA, van der Heijden MW, Kool M, Heijdra BM, Garssen J, Kraneveld AD, Van Loveren H, Roholl P, Saito T, Verbeek JS, Claassens J, Koster AS, Nijkamp FP : Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med 8 : 694 701, 2002
38. Wall JS, Ayoub FM, O'Shea PS : A study of the interactions of an immunoglobulin light chain with artificial and B-lymphocyte membranes. Front Biosci 1 : 46 58, 1996